 Context Therapeutics NASDAQ:CNTX Inc. said Onapristone extended-release ONA-XR has shown significantly increased suppression of tumor cell proliferation in postmenopausal patients with progesterone receptor-positive PR early breast cancer. The positive data came from the window-of-opportunity clinical trial of ONA-XR and was presented during the 2021 San Antonio Breast Cancer Symposium SABCS, the company said in a statement. 